Novo Nordisk to Present Obesity Data in Washington
The company will debut findings from 26 clinical studies at the upcoming ObesityWeek 2026 conference.
Updated on Oct. 31, 2026 in Weight Loss
Live Poll
Do you trust that new weight-loss drugs provide safe and effective long-term health benefits?
Novo Nordisk will showcase data from 26 clinical study abstracts at ObesityWeek 2026 in Washington, D.C., starting November 14, 2026. The research covers a range of obesity portfolio treatments and real-world outcomes.
Why it matters
These presentations provide new insights into experimental weight management therapies and digital support programs. They offer a window into how treatments like CagriSema and semaglutide perform across different demographics and delivery methods.
Novo Nordisk plans to present findings from 26 abstracts, including data on CagriSema dosages of 1.0 mg and 1.7 mg. The research also includes studies on children ages 6 to under 12 and telehealth outcomes measured over 3 and 6 months.
The players
Novo Nordisk
This global healthcare company specializes in treatments for diabetes, obesity, and other serious chronic diseases.
The details
The research includes the REDEFINE 9 trial testing CagriSema and the STEP-YOUNG trial evaluating semaglutide injection in children. Other studies assess digital support programs like SWEEP and the Ro telehealth platform through the OCTANE study.
Timeline
ObesityWeek 2026 will occur from November 14 through November 17, 2026.
The CagriSema REDEFINE 1 trial presentation is scheduled for Saturday, November 14, 2026.
Poster and oral data presentations are set to take place throughout Sunday, November 15, 2026.
Presentations on the STEP-YOUNG trial and Cagrilintide bone mass occur on Monday, November 16, 2026.
Health Landscape
These presentations follow a pattern set by the ObesityWeek 2026 conference for disseminating clinical evidence in the obesity treatment field. The research highlights the industry focus on expanding weight-loss therapies to include younger populations and digital support systems.
While these studies provide critical data for future medical options, CagriSema remains unapproved for use in the United States. Patients should note that investigational semaglutide injections for children under 12 are also not currently available for clinical use.
The takeaway
The research highlights a significant push to gather evidence on new delivery methods and demographic applications for weight management drugs. Patients and providers should wait for formal regulatory review before expecting these specific treatments to become available for prescription.
Further reading
For more information on current developments in medical weight management, visit the Weight Loss section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you trust that new weight-loss drugs provide safe and effective long-term health benefits?
